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ABSTRACT
Introduction: The use of aminoglycosides has
decreased dramatically over several decades in
the United States due to the introduction of
safer Gram-negative agents. This study was
conducted to assess possibly changing
aminoglycoside susceptibility rates between
2006 and 2012 and in reference to 1992 use in
the context of aminoglycoside use volume.
Methods: Quarterly adult use of amikacin,
gentamicin and tobramycin were determined
from the Medical University of South
Carolina Medical Center, Charleston, South
Carolina, USA, pharmacy drug use database
and expressed as total aminoglycoside defined
daily doses per 1,000 patient days for the
years 1992 and 2006 through 2012. Annual
susceptibility of Pseudomonas aeruginosa,
Escherichia coli, and Klebsiella pneumoniae, for
the years 1992, 2006, and 2008 through 2012
were retrieved from our hospital’s clinical
microbiology database (duplicate isolates
were excluded). Quarterly and annualized
aminoglycoside usage rates were compared
to the other years of interest. Likewise,
susceptibility rates of the target organisms to
each aminoglycoside were also compared
across the same timeframe.
Results: While total use of aminoglycosides
decreased slightly from 1992 to 2006, it
increased by about 40% between 2006 and
2008 and then stabilized. Changes in
susceptibility rates between 1992 and 2006
were all B±9% with the exception of K.
pneumoniae susceptibility to amikacin (-17%).
Changes in susceptibility from 1992 to 2012
were also all B±9%. Tobramycin remained the
most active versus P. aeruginosa (%
susceptible = 90), while amikacin remained
most active versus E. coli and K. pneumoniae (%
susceptible = 98 and 98, respectively).
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Conclusion: With low level use of
aminoglycosides in our institution over the
past 2 decades, the susceptibility of key Gram-
negative pathogens has remained relatively
stable, preserving these agents as potential
alternative therapies as resistance arises to
other frequently used antibiotics.
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INTRODUCTION
In the 1970s and 1980s, the aminoglycoside
antibiotics were a key antibiotic group in the
treatment of serious Gram-negative infections.
With the introduction of new beta-lactam agents
with pronounced Gram-negative activity during
the 1980s, the use of aminoglycosides waned as
the less toxic beta-lactams were increasingly
used, and this trend continued into the early
part of this century [1, 2]. The declining use of
one or more of the aminoglycosides was
frequently accompanied by observations of
increasing susceptibility among key pathogens
[3, 4] although this relationship has not held true
in all studies [2]. We are now entering a time in
which we are encountering rapidly increasing
Gram-negative resistance to broad-spectrum
beta-lactams including third and fourth
generation cephalosporins, beta-lactam—beta-
lactamase inhibitor combinations, and the
carbapenems. This rising resistance is often
mediated by extended-spectrum beta-
lactamases (ESBL) and carbapenemases [5–7].
Moreover, the Gram-negative pathogens
producing these enzymes are often co-resistant
to other important antibiotic classes such as the
fluoroquinolones [7–9]. Because of this, it has
been suggested by a number of studies that the
use of aminoglycosides may be increasing as
clinicians search for viable alternative therapies
in treating infections with otherwise resistant
Gram-negative pathogens [10–12]. The purpose
of the present analysis was to assess the level of
aminoglycoside use in adults at our institution
from 2006 through 2012 and, during that same
time period, the level of susceptibility of key
Gram-negative pathogens to this antibiotic class.
METHODS
This study was conducted at the Medical
University of South Carolina Medical Center, a
709-bed academic medical center located in
Charleston, South Carolina, USA. The study
was approved by the Medical University of
South Carolina Medical Center Institutional
Review Board. This article does not contain
any studies with human or animal subjects
performed by any of the authors. Pertinent
data were assembled and analyzed for the
period 2006 through 2012. Susceptibility data
for the years 1992, 2006, and 2008 through 2012
for Pseudomonas aeruginosa, Escherichia coli (non-
urine isolates only), and Klebsiella pneumoniae
were obtained from the hospital’s annual
antibiograms which are produced in
accordance with Clinical and Laboratory
Standards Institute (CLSI) guidance [13]. Thus,
no duplicate or surveillance isolates are
included. Susceptibility was determined by an
automated system (MicroScan WalkAway,
Siemens Medical Solutions USA, Inc., Malvern,
Pennsylvania, USA) in our Clinical Microbiology
Laboratory throughout the period of interest for
E. coli and K. pneumoniae although a change was
made to Kirby–Bauer disk diffusion for P.
aeruginosa in 2007 due to reported inaccuracies
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of automated systems in determining antibiotic
susceptibility of this organism [14]. Systemic,
adult usage data for amikacin, gentamicin and
tobramycin for the years 1992 and 2006 through
2012 were obtained from the Department of
Pharmacy Services drug administration records.
Usage from these records is based on patient
billing such that they account for doses
dispensed but not returned to the pharmacy
(or otherwise wasted) and therefore are, to the
best of our knowledge, administered to the
patients. Susceptibility data were expressed as
percent susceptible and antibiotic usage data
were transformed to defined daily doses (DDD)
presuming the following typical adult doses:
amikacin 15 mg/kg/day; gentamicin and
tobramycin 7 mg/kg/day and assuming an
80 kg adult (DDDs = 1.2, 0.56 and 0.56 g,
respectively) which are more typical to dosing
in this country (as opposed to those DDD
definitions provided by the World Health
Organization). Usage was normalized for
hospital census [DDD/1,000 patient days (PD)].
In addition to these data for 2006 through 2012,
data were also obtained for 1992 to provide a
longer term perspective on potential changes in
use and susceptibility. Although little change in
total aminoglycoside use or susceptibility of the
organisms of interest was noted in the last
4 years of analysis, 2012 values for each was
compared to 1992 levels by Student’s t or Chi-
squared tests as appropriate using Excel for Mac
2011, version 14.3.7 (Microsoft Corporation,
Washington, USA).
RESULTS
Results for antibiotic usage and organism
susceptibility for the years of interest are
presented in Tables 1 and 2, respectively.
Simple visual inspection revealed little
variation in susceptibility of the organisms of
interest between 1992 and 2012 or in the last
4 years of observation and changes were not
statistically significant. Figure 1 is illustrative of
this observation, in this case for P. aeruginosa.
Changes in susceptibility rates between 1992
and 2006 were all B±9% with the exception of
K. pneumoniae susceptibility to amikacin (-
17%). Changes in susceptibility from 1992 to
2012 were also all B±9%. Tobramycin remained
the most active versus P. aeruginosa (%
susceptible = 90), while amikacin remained
most active versus E. coli and K. pneumoniae (%
susceptible = 98 and 98, respectively). While
total aminoglycoside use increased by almost
40% between 1992 and 2012, most of that
increase occurred between 2006 and 2008 with
only a 1% change in total DDD/1,000 PD
between 1992 and 2006 and a 3% increase
occurring between 2008 and 2012, indicating
stable levels of use during that final 5-year
period. The mix of aminoglycosides used did
change between 1992 and later years from a
predominance of amikacin and gentamicin use
to predominant tobramycin use.
DISCUSSION
In distinction to reports from other centers, we
observed little change in the utilization of
aminoglycosides in our institution in recent
years (2008–2012) [1, 2]. Total aminoglycoside
usage did increase almost 40% as compared to
1992 levels, however, and the make-up of total
usage changed from amikacin predominance to
tobramycin predominance over that time
period. Nonetheless, as compared to use of
other antibiotics for Gram-negative infections
at the Medical University of South Carolina
Medical Center, the use of aminoglycosides is
considerably lower. For purposes of comparison,
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our 2012 annual usage of piperacillin/
tazobactam and meropenem were 228.5 and
595.4 DDD/1,000 PD, respectively (with DDDs
defined as 1.5 and 20.25 grams, respectively)
versus 120 DDD/1,000 PD for all
aminoglycosides combined.
Susceptibility of P. aeruginosa, E. coli and K.
pneumoniae to these aminoglycosides did not
change significantly over time either in the last
few years of observation or compared to 1992.
While it has been suggested that there may be an
increased interest and, therefore, use of
Table 1 Aminoglycoside usage for the years 1992 and 2006 through 2012 (deﬁned daily doses/1,000 patient days)
Aminoglycoside Year % Change




Amikacin 41.2 3.4 5.0 4.9 11.6 4.6 10.7 4.7 -88.5 39.2
Gentamicin 46.5 16.6 14.2 24.6 21.4 20.7 23.1 22.9 -50.5 38.3
Tobramycin 32.3 98.8 93.1 133.1 126.0 121.1 130.6 140.0 333.0 41.7
Total 120.0 118.8 112.2 162.6 159.0 146.4 164.3 167.7 39.7 41.2
P – – – – – – – – 0.528 0.135
 Student’s t test; absolute change in DDD/1,000 PD
Table 2 Susceptibility to Aminoglycosides Over Time (% susceptible)
Aminoglycoside Year 1992 2006 2008 2009 2010 2011 2012 P
Pseudomonas aeruginosa
na 306 379 197 235 126 194 180
Amikacin 89 86 86 88 90 89 84 0.382
Gentamicin 71 70 81 85 85 87 80 0.439
Tobramycin 97 91 87 90 91 94 90 0.777
Escherichia coli
na 225 190 161 183 172 161 184
Amikacin 100 97 97 98 98 99 98 0.617
Gentamicin 92 86 85 84 88 90 89 0.630
Tobramycin 98 87 82 83 87 87 89 0.661
Klebsiella pneumoniae
na 166 214 152 163 119 114 113
Amikacin 99 82 93 94 96 98 98 0.597
Gentamicin 87 89 91 94 94 97 95 0.600
Tobramycin 87 79 88 92 92 96 92 0.866
 Chi-squared test; 1992 versus 2012
a Number tested
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aminoglycoside due to the emergence of wide-
spread resistance of Enterobacteriaceae to beta-
lactams mediated by ESBLs and carbapenemase-
producing Enterobacteriaceae [10–12], neither
our observations nor those stemming from
analyses using a collection of academic
medical centers’ data support that theory [1,
2]. In fact, the latter two studies revealed
diminishing use [2]. In the more recent of
these two reports, reflecting use in 29
hospitals, an overall decline of 41% was
reported from 2002 to 2009 [2]. Resistance to
aminoglycoside antibiotics occurs through a
number of mechanisms including enzymatic
modification, decreased cellular penetration,
active efflux and target site alterations with the
former being most common [15]. On that basis,
it is reasonable to consider aminoglycoside
therapy for infections involving Gram-negative
pathogens suspected of producing newer ESBLs
or carbapenemases. However, the observation
that such bacteria often carry resistance
determinants to other antibiotic classes,
including aminoglycosides, fluoroquinolones
and folic acid inhibitors, may undermine that
line of thinking [7–9]. The fact that other broad-
spectrum antibiotic exposure may represent a
risk factor for acquisition and infection by such
organisms only exacerbates the challenge of
identifying suitable therapy [16].
The positive aspect of our findings is perhaps
that susceptibility of these key Gram-negative
pathogens seems to be stable, at least at our
institution. This may well be due to low levels of
use in comparison with other Gram-negative
agents. In fact, tobramycin remains the most
active of our routinely tested antibiotics against
P. aeruginosa while the vast majority of E. coli
and K. pneumoniae are susceptible to amikacin.
Thus, the aminoglycosides merit consideration
in selecting antibiotic therapy for otherwise
resistant Gram-negative pathogens. With our
current level of understanding regarding proper
aminoglycoside dosing, based upon
pharmacodynamics characteristics [12],
aminoglycosides represent potentially effective
and relatively safe antibiotics. At the same time,
it must be noted that a 2009 publication,
Fig. 1 Susceptibility of Pseudomonas aeruginosa over time [% susceptible with 95% conﬁdence interval (CI)]
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reporting susceptibility data for a variety of
bacteria including our organisms of interest
collected and tested from 1999 through 2008,
noted increasing aminoglycoside resistance
[17]. That study collected isolates associated
with serious infections from hospitals across the
United States [17]. While levels of
aminoglycoside use cannot be ascertained,
that report emphasizes the importance of each
hospital determining its own circumstances
with regard to aminoglycoside susceptibility
patterns [17].
The current study is not without limitations.
As this is a single-center analysis, our results
cannot be extrapolated to other hospitals or
healthcare settings. We limited our
investigation to P. aeruginosa, E. coli and K.
pneumoniae as they are all common causes of
healthcare associated infections and are often
multidrug resistant [18]. Obviously, a number
of other Gram-negative and Gram-positive
pathogens are also problematic, multidrug
resistant causes of healthcare associated
infections and were not considered here.
Because we used hospital antibiogram data,
there could be an influence of including
susceptibilities from both infecting and
colonizing organisms on the values, as
opposed to only considering organisms
associated with documented infections.
Further, the exclusion of duplicate isolates in
an antibiogram constructed in compliance with
CLSI guidance would theoretically ignore what
might be more resistant samples thus skewing
susceptibility proportion in a favorable way. We
did not assess the influence of aminoglycoside
‘‘mix’’ (use of which agent predominated at
various times) on resistance trends. Reports
from the 1980s indicated that predominant
use of amikacin at individual institutions
resulted in improved gentamicin and/or
tobramycin susceptibility among Gram-
negative pathogens without a sacrifice in
amikacin susceptibility [19, 20]. Whether the
changes in susceptibility we did observe
between 1992 and 2012 in our pathogens of
interest, none of which were statistically
significant, were related to the change from
predominant amikacin–gentamicin use to
predominant tobramycin use is unknown.
Further, whether these non-statistically
significant changes were also clinically
insignificant is a matter for consideration.
CONCLUSION
Low levels of aminoglycoside use, accompanied
by stable susceptibility patterns in key Gram-
negative pathogens, make these agents viable
for treatment of serious infections for which
other antibiotics may no longer be suitable.
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